Octreotate Radioligand for Imaging Neuroendocrine Tumors

Reference number 5765

Sectors: Biotechnology

Industries: Therapeutics

18F-FET-βAG-TOCA is a novel, ‘click’ 18F-labelled octreotate PET imaging radiopharmaceutical that detects tumour lesions in patients with neuroendocrine tumours (NETs).

Proposed use

18F-FET-βAG-TOCA is clinically safe and has high tumour uptake, showing better resolution than the existing radiotracers in imaging NETs.

Its high production yields and increased accessibility make it suitable for large multicentre studies.

Problem addressed

Compared to radioligand widely used in PET imaging, 68Ga-DOTATATE, 18F-FET-βAG-TOCA is not dependent on availability of 68Ga and so is cheaper and easier to synthesize.

The market for nuclear imaging, driven by increasing demand in personalized healthcare, is worth $2.6 Billion and growing by a CAGR of 3.3%. 18F-FET-βAG-TOCA benefits from better tumour uptake and increased accessibility compared to the in-use 68Ga-DOTATATE and can play an important role in the therapeutic decision-making process of NET patients.

Technology overview

A team at Imperial College London, led by Professor Eric Aboagye, has developed a novel and a highly specific radiotracer that can accurately identify neuroendocrine tumours in patients using the Positron Emission Tomography (PET) scanning platform. The key features include:

18F-FET-βAG-TOCA was generated using ‘click’ chemistry through a triazole-based method. The radioisotope has acceptable metabolic stability with little or no defluorination.

In-human study on patients with NET showed that 18F-FET-βAG-TOCA had no adverse effects on the health. The radiotracer is detectable in the vascular compartment, liver, spleen, kidneys within first 6 minutes of radioligand injection.

While retaining reasonably high binding affinity compared to existing clinically applicable radioligands (68Ga- DOTATATE and 18F FDG), a lower background distribution in liver of 18F-FET-βAG-TOCA was observed in the liver, where metastases is common.


  • Higher penetration and tumour uptake compared to 68Ga-DOTATATE and 18F FDG radioligands
  • Cheap and easy to synthesize
  • Longer half-life and available for large multi-centre studies
  • Specific uptake in somatostatin receptor-high tumours
  • Clinically safe, good biodistribution and better image resolution than clinically applicable imaging agents
  • Improved detection of tumour lesions in patients with NETs

Intellectual property information

The patent protecting the 18F-FET-βAG-TOCA radiotracer has been granted in US and EU. Patent number WO2012118909A1.

Inventor information

Professor Eric Aboagye is a professor at Imperial College and leads the NIHR Biomedical Research Centre Imaging Theme. He was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010 for outstanding contributions to the advancement of medical science. He has also acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.


Dr Rachel Spruce

Industry Partnerships and Commercialisation Executive, Medicine

Rachel is Industry Partnerships and Commercialisation Officer for the Faculty of Medicine.

Contact Rachel

[email protected]

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

A real-time fluorescence probe for Heme Oxygenase activity

A real-time fluorescence probe for Heme Oxygenase activity

Novel heme oxygenase 1 (HO-1) probe compositions, and methods covering easy-to-use and rapid readouts of cell protection in cardiovascular diseases, hemorrhage and red cell disorders. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.